{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:20:58Z","timestamp":1776763258665,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.pharep.2014.08.005","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T23:59:00Z","timestamp":1408751940000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors"],"prefix":"10.1007","volume":"67","author":[{"given":"Chong-Ki","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Shik","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-9809","authenticated-orcid":false,"given":"Dong-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.08.005_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2007.06.006","article-title":"Are statins effective for simultaneously treating dyslipidemias and hypertension?","volume":"196","author":"Koh","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2014.08.005_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11906-007-0032-4","article-title":"Analysis of antihypertensive effects of statins","volume":"9","author":"Milionis","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pharep.2014.08.005_bib0015","first-page":"1191","article-title":"In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2014.08.005_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9149(94)90627-0","article-title":"Clinical implications of the biopharmaceutical properties of fluvastatin","volume":"73","author":"Deslypere","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002280050094","article-title":"In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors","volume":"50","author":"Transon","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2165\/00003495-199753050-00011","article-title":"Atrovastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias","volume":"53","author":"Lea","year":"1997","journal-title":"Drug"},{"key":"10.1016\/j.pharep.2014.08.005_bib0035","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interaction","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharep.2014.08.005_bib0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2165\/00003495-198530030-00002","article-title":"Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders","volume":"30","author":"Sorkin","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2014.08.005_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005344-198601000-00006","article-title":"The renal response to diltiazem and nifedipine: comparison with nitroprusside","volume":"8","author":"Blackshear","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.2510070102","article-title":"Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist","volume":"7","author":"Hamann","year":"1986","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharep.2014.08.005_bib0055","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/0006-2952(89)90517-0","article-title":"In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine","volume":"38","author":"Funaki","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","article-title":"Noninvasive tests of CYP3A enzymes","volume":"4","author":"Watkins","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharep.2014.08.005_bib0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/rcm.2881","article-title":"Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography\/mass spectrometry: application to high-throughput inhibition screening of terpenoids","volume":"21","author":"He","year":"2007","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.pharep.2014.08.005_bib0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.08.005_bib0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharep.2014.08.005_bib0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(24)01402-9","article-title":"Is the role of the small intestine in first-pass metabolism overemphasized?","volume":"51","author":"Lin","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharep.2014.08.005_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharep.2014.08.005_bib0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","article-title":"The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?","volume":"41","author":"Doherty","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharep.2014.08.005_bib0095","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharep.2014.08.005_bib0100","first-page":"1926","article-title":"Tissue distribution of P-glycoprotein encoded by a multidrugresistant gene as revealed by a monoclonal antibody, MRK 16","volume":"48","author":"Sugawara","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharep.2014.08.005_bib0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/37.2.2463300","article-title":"Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein","volume":"37","author":"Thiebaut","year":"1989","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.pharep.2014.08.005_bib0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodebrain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharep.2014.08.005_bib0115","first-page":"231","article-title":"P-glycoprotein and pharmacokinetics","volume":"15","author":"Leveque","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharep.2014.08.005_bib0120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00007691-199608000-00006","article-title":"Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?","volume":"18","author":"Relling","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharep.2014.08.005_bib0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificites and tissues distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.pharep.2014.08.005_bib0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.biopha.2009.04.031","article-title":"Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine","volume":"63","author":"Dorababu","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharep.2014.08.005_bib0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1067\/mcp.2000.104609","article-title":"The interaction of diltiazem with simvastatin","volume":"67","author":"Mousa","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2014.08.005_bib0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(98)90067-4","article-title":"The interaction of diltiazem with lovastatin and pravastatin","volume":"64","author":"Azie","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2014.08.005_bib0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.582","article-title":"Effects of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats","volume":"29","author":"Choi","year":"2008","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharep.2014.08.005_bib0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-007-0447-5","article-title":"Drug interaction between oral atorvastatin and verapamil in healthy subjects; effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil","volume":"64","author":"Choi","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0155","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s12272-009-2015-2","article-title":"Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil, in rats: possible role of P-glycoprotein inhibition by lovastatin","volume":"32","author":"Hong","year":"2009","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.pharep.2014.08.005_bib0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00228-009-0757-x","article-title":"Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin","volume":"66","author":"Choi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0165","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0378-4347(93)E0449-Z","article-title":"Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection","volume":"654","author":"Grundy","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.pharep.2014.08.005_bib0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1016\/j.pharep.2014.08.005_bib0175","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/carcin\/bgn092","article-title":"Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells","volume":"29","author":"Han","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharep.2014.08.005_bib0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF01062108","article-title":"Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level\u2013time curve","volume":"6","author":"Chiou","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.pharep.2014.08.005_bib0185","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1124\/jpet.300.3.1036","article-title":"Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4","volume":"300","author":"Cummins","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.08.005_bib0190","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"10","author":"Wolozin","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharep.2014.08.005_bib0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/156800605774962112","article-title":"A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence","volume":"5","author":"Mason","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1016\/j.pharep.2014.08.005_bib0200","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0090-9556(25)08192-9","article-title":"Biotransformation of lovastatin. V, Species differences in in vivo metabolite profiles of mouse, rat, dog, and human","volume":"21","author":"Halpin","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2014.08.005_bib0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1023\/A:1011036428972","article-title":"HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein","volume":"18","author":"Wang","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharep.2014.08.005_bib0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03190040","article-title":"Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4","volume":"24","author":"Kelly","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharep.2014.08.005_bib0215","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1734-1140(11)70724-1","article-title":"Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-gp and CYP3A4 inhibition by simvastatin","volume":"63","author":"Choi","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2014.08.005_bib0220","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/00498250010021684","article-title":"Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man","volume":"30","author":"Bogaards","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharep.2014.08.005_bib0225","series-title":"Cytochromes P450. Structure, Function, and Mechanism","first-page":"122","article-title":"Cytochrome P450. Substrate specificity and metabolism","author":"Lewis","year":"1996"},{"key":"10.1016\/j.pharep.2014.08.005_bib0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1750-3841.2010.01960.x","article-title":"Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats","volume":"76","author":"Wang","year":"2011","journal-title":"J Food Sci"},{"key":"10.1016\/j.pharep.2014.08.005_bib0235","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jps.10086","article-title":"Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs","volume":"91","author":"Kuroha","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharep.2014.08.005_bib0240","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1248\/jhs.56.310","article-title":"Pharmacokinetic interaction between nifedipine and Coenzyme Q10 in rats: a new type of drug-supplement interaction","volume":"56","author":"Nishimura","year":"2010","journal-title":"J Health Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:40Z","timestamp":1752611740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.08.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1734114014002667"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.08.005","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}